These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

466 related items for PubMed ID: 17645704

  • 1. Risk factors for impaired wound healing in sirolimus-treated renal transplant recipients.
    Knight RJ, Villa M, Laskey R, Benavides C, Schoenberg L, Welsh M, Kerman RH, Podder H, Van Buren CT, Katz SM, Kahan BD.
    Clin Transplant; 2007; 21(4):460-5. PubMed ID: 17645704
    [Abstract] [Full Text] [Related]

  • 2. Steroid withdrawal five days after renal transplantation allows for the prevention of wound-healing complications associated with sirolimus therapy.
    Sandrini S, Setti G, Bossini N, Maffei C, Iovinella L, Tognazzi N, Maffeis R, Nodari F, Portolani N, Cancarini G.
    Clin Transplant; 2009; 23(1):16-22. PubMed ID: 18727661
    [Abstract] [Full Text] [Related]

  • 3. Sirolimus does not increase the risk for postoperative thromboembolic events among renal transplant recipients.
    Langer RM, Kahan BD.
    Transplantation; 2003 Jul 27; 76(2):318-23. PubMed ID: 12883185
    [Abstract] [Full Text] [Related]

  • 4. Intraoperative placing of drains decreases the incidence of lymphocele and deep vein thrombosis after renal transplantation.
    Derweesh IH, Ismail HR, Goldfarb DA, Araki M, Zhou L, Modlin C, Krishnamurthi V, Flechner SM, Novick AC.
    BJU Int; 2008 Jun 27; 101(11):1415-9. PubMed ID: 18190623
    [Abstract] [Full Text] [Related]

  • 5. Comparison of sirolimus plus tacrolimus versus sirolimus plus cyclosporine in high-risk renal allograft recipients: results from an open-label, randomized trial.
    Gaber AO, Kahan BD, Van Buren C, Schulman SL, Scarola J, Neylan JF, Sirolimus High-Risk Study Group.
    Transplantation; 2008 Nov 15; 86(9):1187-95. PubMed ID: 19005398
    [Abstract] [Full Text] [Related]

  • 6. Incidence of delayed graft function and wound healing complications after deceased-donor kidney transplantation is not affected by de novo everolimus.
    Albano L, Berthoux F, Moal MC, Rostaing L, Legendre C, Genin R, Toupance O, Moulin B, Merville P, Rerolle JP, Bayle F, Westeel PF, Glotz D, Kossari N, Lefrançois N, Charpentier B, Blanc AS, Di Giambattista F, Dantal J, RAD A2420 Study Group.
    Transplantation; 2009 Jul 15; 88(1):69-76. PubMed ID: 19584683
    [Abstract] [Full Text] [Related]

  • 7. A retrospective study of conversion from tacrolimus-based to sirolimus-based immunosuppression in orthotopic liver transplant recipients.
    Yu S, He X, Yang L, Ma Y, Zhu X, Ju W, Huang J.
    Exp Clin Transplant; 2008 Jun 15; 6(2):113-7. PubMed ID: 18816237
    [Abstract] [Full Text] [Related]

  • 8. Sirolimus-based triple immunosupression with antithymocyte globulin induction in expanded criteria donor kidney transplantation.
    Uslu A, Nart A, Taşli FA, Postaci H, Aykas A, Doğan M, Sahin T.
    Nephrology (Carlton); 2008 Feb 15; 13(1):80-6. PubMed ID: 18199109
    [Abstract] [Full Text] [Related]

  • 9. A long-term study on hyperlipidemia in stable renal transplant recipients.
    Tse KC, Lam MF, Yip PS, Li FK, Lai KN, Chan TM.
    Clin Transplant; 2004 Jun 15; 18(3):274-80. PubMed ID: 15142048
    [Abstract] [Full Text] [Related]

  • 10. Statins benefit outcomes of renal transplant recipients on a sirolimus-cyclosporine regimen.
    Lisik W, Schoenberg L, Lasky RE, Kahan BD.
    Transplant Proc; 2007 Dec 15; 39(10):3086-92. PubMed ID: 18089328
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Thymoglobulin, sirolimus, and reduced-dose cyclosporine provides excellent rejection prophylaxis for pancreas transplantation.
    Knight RJ, Kerman RH, Zela S, Podder H, Van Buren CT, Katz S, Kahan BD.
    Transplantation; 2003 Apr 27; 75(8):1301-6. PubMed ID: 12717220
    [Abstract] [Full Text] [Related]

  • 13. The effects of sirolimus on wound healing in dermatologic surgery.
    Brewer JD, Otley CC, Christenson LJ, Phillips PK, Roenigk RK, Weaver AL.
    Dermatol Surg; 2008 Feb 27; 34(2):216-23. PubMed ID: 18093198
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Sirolimus delays recovery from posttransplant renal failure in kidney graft recipients.
    Boratyńska M, Banasik M, Patrzalek D, Szyber P, Klinger M.
    Transplant Proc; 2005 Mar 27; 37(2):839-42. PubMed ID: 15848550
    [Abstract] [Full Text] [Related]

  • 16. The influence of various maintenance immunosuppressive drugs on lymphocele formation and treatment after kidney transplantation.
    Goel M, Flechner SM, Zhou L, Mastroianni B, Savas K, Derweesh I, Patel P, Modlin C, Goldfarb D, Novick AC.
    J Urol; 2004 May 27; 171(5):1788-92. PubMed ID: 15076277
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. The utilization of sirolimus and the impact on wound-healing complications in obese kidney transplant recipients.
    Hulbert AL, Delahunty AJ, Rajab A, Forbes RC, Winters HA.
    Clin Transplant; 2013 May 27; 27(4):E521-7. PubMed ID: 23923974
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 24.